Chronic Leukemia Clinical Trial
Official title:
Study of Predictive Immunological Parameters of Molecular Complete Remission in Patients With Chronic Myelogenous Leukemia in Chronic Phase and Treated With Tyrosine Kinase Inhibitor
The investigators recently identified promiscuous HLA-DR-derived epitopes from the human telomerase reverse transcriptase (TERT) called universal cancer peptides (UCP), to study tumor-specific CD4+ T cell responses. The aim of this prospective preliminary study is to evaluate the presence of UCP-specific Th1 responses in patients in complete remission of CML two years after end of Tyrosine Kinase Inhibitor (TKi) treatments.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03588936 -
Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant
|
Phase 1 | |
| Recruiting |
NCT01472055 -
Pharmacokinetic Study of Fludarabine in Pediatric Hematopoietic Stem Cell Transplantation
|
Phase 2 | |
| Recruiting |
NCT05645510 -
LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study
|
||
| Recruiting |
NCT06063603 -
Evaluation of a Pain Management Intervention Preparatory to a Future Pragmatic Trial, ASCENT Study
|
N/A | |
| Terminated |
NCT01598025 -
Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor
|
N/A | |
| Active, not recruiting |
NCT00899223 -
Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes
|
||
| Terminated |
NCT01624701 -
Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01800643 -
Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03016806 -
Umbilical Cord Blood Transplantation From Unrelated Donors
|
Phase 1 | |
| Completed |
NCT01362985 -
Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of Plerixafor
|
Phase 4 | |
| Completed |
NCT00230282 -
Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia
|
Phase 2 | |
| Completed |
NCT02169791 -
Nonmyeloablative Haploidentical Transplant Followed by MLN9708
|
Phase 2 | |
| Completed |
NCT02451592 -
Fungemia in Hematologic Malignancies
|
N/A | |
| Completed |
NCT00273936 -
Trial of AVN-944 in Patients With Advanced Hematologic Malignancies
|
Phase 1 | |
| Recruiting |
NCT04965649 -
Is There an Association Between Innate CD8+ T Cells and the Evolution of Tyrosine Kinase Inhibitor Resistance Mutations in Phi+ Hematological Malignancies.
|
||
| Completed |
NCT01336712 -
Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases
|
Phase 2 |